Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H2 2017

Publisher Name :
Date: 12-Sep-2017
No. of pages: 209
Inquire Before Buying

Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H2 2017, provides an overview of the Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline landscape.

H1N1 Infection also called as swine flu is a new kind of flu in humans. It's caused by a contagious virus. H1N1 flu infects the breathing tubes in nose, throat, and lungs. The disease is contagious. When people who have it cough or sneeze, they spray tiny drops of the virus into the air. Signs and symptoms include cough, fever, sore throat, stuffy or runny nose, body aches, headache and fatigue. Treatment includes medication (antiviral drugs).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H1N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 10, 7, 7, 1, 47, 6 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 2, 1, 11 and 3 molecules, respectively.

Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H1N1 Subtype Infections (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H2 2017

Table of Contents
Table of Contents 2
Introduction 5
Influenza A Virus, H1N1 Subtype Infections - Overview 6
Influenza A Virus, H1N1 Subtype Infections - Therapeutics Development 7
Influenza A Virus, H1N1 Subtype Infections - Therapeutics Assessment 21
Influenza A Virus, H1N1 Subtype Infections - Companies Involved in Therapeutics Development 29
Influenza A Virus, H1N1 Subtype Infections - Drug Profiles 50
Influenza A Virus, H1N1 Subtype Infections - Dormant Projects 182
Influenza A Virus, H1N1 Subtype Infections - Discontinued Products 185
Influenza A Virus, H1N1 Subtype Infections - Product Development Milestones 186
Appendix 198

List of Tables
Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by AbbVie Inc, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Adimmune Corp, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Akshaya Bio Inc, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Altimmune Inc, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Antigen Express Inc, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by BioCryst Pharmaceuticals Inc, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Cadila Healthcare Ltd, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by CEL-SCI Corp, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Cilian AG, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Cocrystal Pharma Inc, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by ContraFect Corp, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Curevac AG, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by EpiVax Inc, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Etubics Corp, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Gemmus Pharma Inc, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Genentech Inc, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by iBio Inc, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Johnson & Johnson, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Kineta Inc, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Lakewood-Amedex Inc, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Medicago Inc, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by MedImmune LLC, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Microbiotix Inc, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Mucosis BV, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by NanoViricides Inc, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by NewLink Genetics Corp, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Novavax Inc, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by OPKO Health Inc, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by PeptiDream Inc, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Recce Ltd, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Sanofi, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Sanofi Pasteur SA, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Sarepta Therapeutics Inc, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by SK Chemicals Co Ltd, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by TechnoVax Inc, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Touchlight Genetics Ltd, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Vaccibody AS, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Vaxart Inc, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Vironova AB, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Visterra Inc, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Dormant Projects, H2 2017
Influenza A Virus, H1N1 Subtype Infections - Dormant Projects, H2 2017 (Contd..1), H2 2017
Influenza A Virus, H1N1 Subtype Infections - Dormant Projects, H2 2017 (Contd..2), H2 2017
Influenza A Virus, H1N1 Subtype Infections - Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017
  • Global Drugs for Clostridium Difficile Infections Sales Market Report 2017
    Published: 15-Sep-2017        Price: US 4000 Onwards        Pages: 124
    In this report, the global Drugs for Clostridium Difficile Infections market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Drugs for Clostridium Difficile Infections for these regions, from 2012 to 2022 (forecast), covering - United Sta......
  • Global Polymixin Market Research Report 2017
    Published: 14-Sep-2017        Price: US 2900 Onwards        Pages: 107
    In this report, the global Polymixin market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Polymixin in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - Japan - ......
  • Global Cephalosporin Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 14-Sep-2017        Price: US 3480 Onwards        Pages: 118
    "Cephalosporin is an antibiotic medication commonly prescribed to treat several different types of infections. Cephalosporin originally derived from the fungus Acremonium, which was previously known as ""Cephalosporium""." Scope of the Report: This report focuses on the Cephalosporin in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions,......
  • Global Cefazolin Sodium Market Research Report 2017
    Published: 13-Sep-2017        Price: US 2900 Onwards        Pages: 115
    In this report, the global Cefazolin Sodium market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Cefazolin Sodium in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - J......
  • Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H2 2017
    Published: 12-Sep-2017        Price: US 2000 Onwards        Pages: 51
    Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Lassa Fever - Pipeline Review, H2 2017, provides an overview of the Lassa Fever (Infectious Disease) pipeline landscape. Lassa fever is an acute viral hemorrhagic illness caused by Lassa virus, a member of the arenavirus family of viruses. It is transmitted to humans from contacts with food or house......
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2017
    Published: 12-Sep-2017        Price: US 2000 Onwards        Pages: 264
    Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2017, provides an overview of the Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline landscape. Ebola is a rare but deadly viral infection that causes bleeding inside and outside the body. Sign......
  • Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H2 2017
    Published: 12-Sep-2017        Price: US 2000 Onwards        Pages: 78
    Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H2 2017, provides an overview of the Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline landscape. Marburg hemorrhagic fever is a rare, acute infectious which affects both human and no......
  • Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H2 2017
    Published: 12-Sep-2017        Price: US 2000 Onwards        Pages: 74
    Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H2 2017, provides an overview of the Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline landscape. Epstein-Barr virus (EBV), also known as human herpesvirus 4, is a member of the herpes virus family. It is one of the most comm......
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2017
    Published: 12-Sep-2017        Price: US 2000 Onwards        Pages: 151
    Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2017, provides an overview of the Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline landscape. H5N1 is a type of influenza virus that causes a highly infectious, severe respiratory disease in birds called av......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs